Nightstar Therapeutics plc
Healthcare · Biological Products, (No Diagnostic Substances) · X0 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | |
|---|---|---|
| Revenue | — | — |
| Operating income | — | — |
| Net income | −$14.4M | −$3.5M |
| Total assets | $180.0M | $135.2M |
| Total liabilities | $14.4M | $9.4M |
| Equity | $165.6M | $125.8M |
| EPS (diluted) | — | — |
| Shares out. | 33.5M | 28.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −8.7%
- Return on assets
- −8.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 8.0%
- Debt / equity
- 0.09×
- Book value / share
- $4.95
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Accruals / assets
- 17.4%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 1 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 10, 2019
- Other material eventMay 29, 2019
- Shareholder vote · Other material eventMay 8, 2019
- Entered a material agreement · Other material eventMar 4, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASCHEDULE 13G/AFeb 14, 2020
- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GFeb 4, 2020
- 15-12BJun 17, 2019
- SC 13D/ANEW ENTERPRISE ASSOCIATES 15, L.P. - NIGHTSTAR THERAPEUTICS PLC 13D/A(#3)Jun 12, 2019
- 4FORM 4 SUBMISSIONJun 11, 2019
- S-8 POSJun 10, 2019
- S-8 POSJun 10, 2019
- 8-KJun 10, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019
- 4FORM 4 SUBMISSIONJun 7, 2019